ECM Modified Nerve Graft via Decellularization for Peripheral Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tissue engineered nerve grafts face limitations such as immunogenicity from allogeneic cells, complex preparation methods, and inadequate biological effects due to unclear in vivo fate and properties of support cells, which hinder their clinical application for peripheral nerve repair.
Innovation Solution
The development of cell-derived ECM modified tissue engineered nerve grafts using a rotational cell reactor to culture support cells within a nerve conduit, followed by decellularization to generate ECM, creating a biocompatible and immunogenicity-reduced graft that promotes axonal regeneration and neural cell adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If allogeneic cells are used in tissue engineered nerve grafts, then cell supply and structural support are improved, but immunogenicity increases
Solution Approach 1:
The patent extracts only the extracellular matrix (ECM) from allogeneic tissue by removing all cells through decellularization processes. This preserves the beneficial structural and biochemical properties of the ECM while eliminating the immunogenic cellular components, thereby resolving the contradiction between obtaining sufficient material and avoiding immune rejection.
Solution Approach 2:
The ECM acts as an intermediary between the donor tissue and the recipient's immune system. By using cell-free ECM as a scaffold, it provides structural support and biochemical cues for nerve regeneration without triggering immune responses, mediating between the need for structural integrity and the requirement for immunocompatibility.
2Manufacturing precision
If complex preparation methods are used to create tissue engineered nerve grafts, then structural precision and biological functionality are improved, but manufacturing complexity and processing time increase
Solution Approach 1:
The patent performs decellularization and ECM preparation in advance before the grafting procedure. The allogeneic tissue is pre-processed to remove cells and retain ECM, which can then be sterilized, stored, and ready for implantation. This preliminary action simplifies the actual surgical procedure while maintaining high structural precision.
Solution Approach 2:
The patent discards the cellular components of allogeneic tissue through systematic decellularization processes while recovering and preserving the ECM framework. This selective discarding and recovery approach simplifies the preparation by removing complex cellular elements that would require complex handling, while retaining the essential structural component.
3Reliability
If support cells are implanted in tissue engineered nerve grafts, then neural support and regeneration promotion are improved, but uncertainty about in vivo fate and biological effects increases
Solution Approach 1:
The patent enables the ECM scaffold to serve itself by incorporating biochemical cues and structural features that naturally guide nerve regeneration without requiring implanted support cells. The ECM's inherent properties, such as growth factor binding sites and appropriate mechanical characteristics, provide self-sufficient support for neural regeneration, eliminating the uncertainty associated with implanted cell behavior.
Data Source
Figure 1A~3C
Figure 4A~5C
Figure 6
AI summary
A tissue engineered nerve graft for repairing peripheral nerve injury consists of a nerve conduit and a extracellular matrix (ECM) that is secreted by autologous or allogeneic support cells and obtained by decellularization. A preparation method of the ECM-modified tissue engineered nerve grafts containing support cells, nerve conduit and constructing a ECM-modified tissue engineered nerve graft.